Back New EDQM document on recombinant viral vectored vaccines to support COVID-19 vaccine developers

EDQM Strasbourg, France 03/11/2020
  • Diminuer la taille du texte
  • Augmenter la taille du texte
  • Imprimer la page
  • Imprimer en PDF

A broad range of technologies are being evaluated in the development of COVID-19 vaccines, from conventional approaches, such as live attenuated and inactivated vaccines, to more recent technologies, such as nucleic acid vaccines and recombinant viral vectored vaccines. Currently, limited guidance is available covering the quality of such new technologies.

The EDQM has drafted a text on the control of viral vectored vaccines in order to support COVID-19 vaccine developers currently working on candidate vaccines based on this technology. This work was accomplished in collaboration with the European Pharmacopoeia (Ph. Eur.) Group of Experts on vaccines for human use (Group 15), which is composed of experts from licensing authorities, national control laboratories, academia and industry from Europe and beyond (including the United States Food and Drug Administration, Health Canada and the Therapeutic Goods Administration, Australia).

For more information, read the related press release.

See also: